Kennan C. Marsh

Kennan C. Marsh

Auto-generated profile, based on publicly available information

Kennan C. Marsh

Research and Development, AbbVie, Inc, North Chicago, IL 60064, USA

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2008 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ASAlex R. Shoemaker
Alex R. Shoemaker
MMMichael J. Mitten
Michael J. Mitten
JAJessica Adickes
Jessica Adickes
SAScott Ackler
Scott Ackler
MRMarion Refici
Marion Refici
SESteven W. Elmore
Steven W. Elmore
Purpose: The purpose of this study was to characterize the activity of the Bcl-2 protein family inhibitor ABT-263 in a panel of small cell lung cancer (SCLC) xenograft models. Experimental Design: A panel of 11 SCLC xenograft models was established to evaluate the efficacy of ABT-263. Single agent activity was examined on a continuous dosing schedule in each of these models. The H146 model was used to further evaluate dose and schedule, comparison to standard cytotoxic agents, and induction of apoptosis. Results: ABT-263 exhibited a range of antitumor activity, leading to complete tumor regression in several models. Significant regressions of tumors as large as 1 cc were also observed. The efficacy of ABT-263 was also quite durable; in several cases, minimal tumor regrowth was noted several weeks after the cessation of treatment. Antitumor effects were equal or superior to that of several clinically approved cytotoxic agents. Regression of large established tumors was observed through several cycles of therapy and efficacy was retained in a Pgp-1 overexpressing line. Significant efficacy was observed on several dose and therapeutic schedules and was associated with significant induction of apoptosis. Conclusions: ABT-263 is a potent, orally bioavailable inhibitor of Bcl-2 family proteins that has recently entered clinical trials. The efficacy data reported here suggest that SCLC is a promising area of clinical investigation with this agent.

13 March 2019 in Science Translational Medicine
Verified
Journal Article
Open access
PDF file
MTMark J. Taylor
Mark J. Taylor
TGThomas W. von Geldern
Thomas W. von Geldern
LFLouise Ford
Louise Ford
Marc Peter HübnerMarc Peter Hübner
Marc Peter Hübner
KMKennan Marsh
Kennan Marsh
SWStephen A. Ward
Stephen A. Ward
An oral macrolide drug targeting the bacterial endosymbiont, Wolbachia , shows efficacy against filarial nematodes in preclinical animal models.

26 March 2020 in International Journal for Parasitology
Verified
Journal Article
Closed access
RCRyan Choi
Ryan Choi
MHMatthew A. Hulverson
Matthew A. Hulverson
WHWenlin Huang
Wenlin Huang
RVRama S.R. Vidadala
Rama S.R. Vidadala
GWGrant R. Whitman
Grant R. Whitman
WVWesley C. Van Voorhis
Wesley C. Van Voorhis

1 October 2004 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
ASAndrew Souers
Andrew Souers
DWDariusz Wodka
Dariusz Wodka
JGJu Gao
Ju Gao
JLJared C. Lewis
Jared C. Lewis
AVAnil Vasudevan
Anil Vasudevan
PKPhilip R. Kym
Philip R. Kym

11 March 2006 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PKPhilip R. Kym
Philip R. Kym
ASAndrew Souers
Andrew Souers
TCThomas J. Campbell
Thomas J. Campbell
JLJohn K. Lynch
John K. Lynch
AJAndrew S. Judd
Andrew S. Judd
JPJames S. Polakowski
James S. Polakowski

1 August 2019 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
PDF file
MKMatthew P. Kosloski
Matthew P. Kosloski
DBDaniel A.J. Bow
Daniel A.J. Bow
RKRyota Kikuhchi
Ryota Kikuhchi
HWHaoyu Wang
Haoyu Wang
EKElaine J. Kim
Elaine J. Kim
WLWei Liu
Wei Liu
Glecaprevir and pibrentasvir are oral direct-acting antiviral agents approved in combination for treatment of chronic hepatitis C viral infection. In vitro studies identified the combination as potential clinically relevant inhibitors of the efflux transporters P glycoprotein (P-gp), breast cancer resistance protein (BCRP), and hepatic uptake transporters organic anion transporting polypeptide (OATP) 1B1/3. Glecaprevir inhibited P-gp, BCRP, OATP1B1, and OATP1B3 with IC50 values of 0.33, 2.3, 0.017, and 0.064 µM, respectively. Pibrentasvir inhibited P-gp, BCRP, and OATP1B1 with IC50 values of 0.036, 14, and 1.3 µM, respectively. Neither agent inhibited organic cation transporter (OCT) 1, OCT2, organic anion transporter (OAT) 1, OAT3, multidrug and toxin extrusion (MATE) 1, or MATE2K. Open-label Phase 1 clinical drug-drug interaction studies were conducted in healthy subjects to evaluate interaction potential of glecaprevir/pibrentasvir and coadministered selective substrates for P-gp (digoxin, dabigatran etexilate, sofosbuvir), BCRP (rosuvastatin, sofosbuvir), and OATP1B1/3 (pravastatin, rosuvastatin). Pharmacokinetic parameters maximum plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC) were evaluated for probe substrates alone and in combination with glecaprevir/pibrentasvir. Cmax central values increased by 72%, 105%, 123%, 462%, and 66% for digoxin, dabigatran, pravastatin, rosuvastatin, and sofosbuvir, respectively. AUC central values increased by 48%, 138%, 130%, 115%, and 125% for digoxin, dabigatran, pravastatin, rosuvastatin, and sofosbuvir, respectively. Exposure of sofosbuvir metabolite GS-331007 was similar with or without glecaprevir/pibrentasvir. Outcomes of the clinical drug-drug interaction studies confirmed clinically relevant inhibition of P-gp, BCRP, and OATP1B1/3, and were used to provide dosing guidance for the concomitant use of glecaprevir/pibrentasvir with relevant transporter substrates. SIGNIFICANCE STATEMENT N/A